In the medical literature there case reports that Harvoni improves symptoms in patients with
PCT. However, this has never been systematically tested. Therefore, the purpose of this study
is to assess whether Harvoni alone is an effective therapy of active PCT in patients with
Chronic Hepatitis C.
Phase:
Phase 2
Details
Lead Sponsor:
Wake Forest University Health Sciences
Collaborators:
Gilead Sciences National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institutes of Health (NIH)
Treatments:
Ledipasvir Ledipasvir, sofosbuvir drug combination Sofosbuvir